Actively Recruiting
Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism
Led by University Hospital, Brest · Updated on 2024-12-16
1276
Participants Needed
20
Research Sites
521 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Brest
Lead Sponsor
M
Ministry of Health, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Venous thromboembolism (VTE) can be the earliest sign of cancer. Identifying occult cancers at the time of VTE diagnosis may lead to significant improvement of patients' care. This is also an upmost issue for patients who want to know if an underlying cancer might have triggered the VTE. An individual patient-level data meta-analysis (IPDMA) supports extensive screening strategies for occult cancer especially based on FDG PET/CT, and suggests that the best target population for cancer screening would be patients with unprovoked VTE older than 50 years of age (6.7% in patients aged 50 years or more vs. 1.0% in patients of less than 50 years (OR: 7.1, 95% CI: 3.1 to 16%).
CONDITIONS
Official Title
Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 50 years or older with a new diagnosis of first unprovoked proximal deep vein thrombosis and/or pulmonary embolism
- Unprovoked VTE defined by absence of active malignancy within last 5 years (except treated basal or squamous cell carcinoma)
- No recent (less than 3 months) paralysis, weakness, or immobilization of lower limbs
- No recent bedridden status for 3 or more days, major surgery, or anesthesia within previous 12 weeks
- No previous unprovoked VTE
- No known hereditary or acquired thrombophilia
You will not qualify if you...
- Refusal or inability to provide informed consent
- Hypersensitivity to 18F-FDG or any of its excipients
- Inability to comply with follow-up requirements
- Venous thromboembolism occurring while on anticoagulation treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
University of Calgary
Calgary, Alberta, Canada
Not Yet Recruiting
2
University of Manitoba
Winnipeg, Manitoba, Canada
Not Yet Recruiting
3
McMaster University
Hamilton, Ontario, Canada
Not Yet Recruiting
4
London Health Sciences Centre
London, Ontario, Canada
Not Yet Recruiting
5
Hopital Montfort
Ottawa, Ontario, Canada
Actively Recruiting
6
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Actively Recruiting
7
Sunnybrook Research Institute
Toronto, Ontario, Canada
Actively Recruiting
8
University Health Network
Toronto, Ontario, Canada
Actively Recruiting
9
Jewish General Hospital
Montreal, Quebec, Canada
Actively Recruiting
10
McGill University Health Centre
Montreal, Quebec, Canada
Not Yet Recruiting
11
CH des Pays de Morlaix
Morlaix, France, France, 29600
Actively Recruiting
12
CH Agen
Agen, France
Actively Recruiting
13
CHU Angers
Angers, France
Actively Recruiting
14
Brest University Hospital
Brest, France
Actively Recruiting
15
CHU de Clermont-Ferrand
Clermont-Ferrand, France
Actively Recruiting
16
CHU de Dijon
Dijon, France
Actively Recruiting
17
CHU de Limoges
Limoges, France
Actively Recruiting
18
Hôpital Européen Georges Pompidou
Paris, France
Actively Recruiting
19
CHU Saint-Etienne
Saint-Etienne, France
Actively Recruiting
20
Hôpital Saint Musse - CH Toulon
Toulon, France
Actively Recruiting
Research Team
P
Pierre-Yves SALAUN
CONTACT
A
Aurélien DELLUC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here